Search clinical trials for: Everolimus and mycophenolate sodium

Total 11423 results

University Hospital Freiburg

Unknown

Safety Study of Calcineurin Inhibitor Free GvHD Prophylaxis in Allogeneic Stem Cell Transplantation

Hematologic Diseases

Germany
University of Giessen
Novartis; Hoffmann-La Roche; Astellas Pharma Inc; Heidelberg University

Completed

Impact of Immunosuppressive Regimens on Polyomavirus-related Transplant Nephropathy

Polyomavirus Infections

Germany
Seung-Jung Park
Abbott Medical Devices; CardioVascular Research Foundation, Korea

Terminated

Bypass Surgery Versus Everolimus-Eluting Stent Implantation for Multivessel Coronary Artery Disease (BEST) (BEST)

Coronary Artery Disease

Thailand, Korea, Republic of, China, Malaysia
Charite University, Berlin, Germany
Novartis

Completed

Pharmacokinetics of Everolimus and Enteric-Coated Mycophenolatesodium Before and After Withdrawal of Cyclosporine in Renal Transplant Patients

Renal Transplantation

Germany
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.

Renal Transplantation

France
Novartis Pharmaceuticals

Completed

Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance

Renal Transplantation

United States
Novartis Pharmaceuticals

Completed

A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatment of Afinitor (OSAT)

Metastatic Renal Cell Carcinoma (mRCC)

Norway
Centre Hospitalier Universitaire, Amiens
Novartis

Unknown

Comparison of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI)Versus a CNI-free Treatment in Renal Transplantation (CIME) (CIME)

Kidney Failure

France
Novartis Pharmaceuticals

Completed

A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Japan
University of Bologna

Unknown

Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy (PROTECT)

Heart Transplantation | Cytomegalovirus Infection | Cardiac Allograft Vasculopathy

Italy
Hospital Vall d'Hebron

Completed

The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation

Hepatitis C Recurrence After Liver Transplant

Spain
Novartis Pharmaceuticals

Completed

A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients (MANDELA)

Heart Transplantation

Germany
Novartis Pharmaceuticals

Completed

Everolimus in de Novo Heart Transplant Recipients (EVERHEART)

Cardiac Transplantation

Italy
Novartis Pharmaceuticals

Completed

ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients

Renal Transplantation

Switzerland
Poitiers University Hospital

Completed

Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function

Chronic Kidney Disease

France
Irmandade Santa Casa de Misericórdia de Porto Alegre
Novartis

Completed

A Prospective Study to Investigate Mycophenolic Acid (MPA) Exposure Through Area Under the Curve (AUC) in Renal Transplants Recipients Treated With Mycophenolate Mofetil (MMF) and After Conversion to Mycophenolate Sodium (EC-MPS) (AUC-MPA)

Renal Transplantation

Brazil
University of Pennsylvania
Novartis Pharmaceuticals

Terminated

Myfortic or CellCept Gastrointestinal Effects in African American Kidney Recipients

Transplants and Implants

United States
Novartis

Completed

Gastrointestinal and Health-related Quality of Life in Kidney Transplant Patients Treated With Mycophenolate Mofetil

Maintenance Kidney Transplant

Switzerland
Fundação Pró Rim

Unknown

Evaluation of Early Use of Everolimus (EVE) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients

Cytomegalovirus Infections
The Netherlands Cancer Institute

Active, not recruiting

Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin

Neuroendocrine Carcinomas

Netherlands
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC (TRACER)

Hepatocellular Carcinoma

Hong Kong, Taiwan, Thailand
University of Zurich
Novartis Pharmaceuticals

Recruiting

Intracoronary Analysis of Cardiac Allograft Vasculopathy by Means of Optical Coherence Tomography (OCTandCAV)

Immunosuppression | Intimal Proliferation

Switzerland
German Breast Group
Novartis

Terminated

Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane (Evelyn)

Metastatic Breast Cancer

Germany
University Medical Center Groningen
Radboud University Medical Center; Universitaire Ziekenhuizen KU Leuven; UMC... and other collaborators

Active, not recruiting

RCT Comparing Immunosuppressive Regimens in Elderly Renal Transplant Recipients (OPTIMIZE)

Elderly Patients | Immunosuppression | Renal Transplant Recipients

Netherlands, Belgium
Chong Kun Dang Pharmaceutical

Unknown

Efficacy and Safety of Everolimus Versus Mycophenolate Mofetil in Liver Transplant Recipients. (MONTBLANC)

Liver Transplant

Korea, Republic of
Novartis Pharmaceuticals

Completed

Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) (EXIST-2)

Lymphangioleiomyomatosis (LAM) | Tuberous Sclerosis Complex (TSC)

United States, United Kingdom, Germany, Italy, Russian Federation, Netherlands, Japan, Canada, Poland, France, Spain
Aga Khan University
Zeenat Qureshi Stroke Institute

Recruiting

Best Solution Identification to Prevent Hyperchloremia Combinations of Sodium Chloride and Sodium Acetate IV Fluids Along With Standard of Care Treatment in Acute Stroke Patients (sodium acetate)

Stroke, Acute

Pakistan
University of Luebeck

Terminated

Bioresorbable Vascular Scaffolds Versus Stents in Patients With Chronic Total Occlusion (SCORE-CTO)

Coronary Artery Disease

Germany
Novartis Pharmaceuticals

Completed

Enteric-Coated Mycophenolate Sodium on Quality of Life in Patients With Gastrointestinal Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation

Renal Transplant

United Kingdom
Fundacion Investigacion y Desarrollo

Unknown

Study to Evaluate Effect of Everolimus in Progression of Graft Vascular Illness on Patients With Heart Transplant (EVEROSTAT)

Cardiac Transplant

Spain
Novartis Pharmaceuticals

Completed

12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients (ATHENA)

Kidney Transplantation | Renal Transplantation

Germany, France
Novartis Pharmaceuticals

Terminated

Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma (CATChEz)

Carcinoma, Renal Cell

Australia, Korea, Republic of
Northwestern University
Novartis

Completed

Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens

End Stage Renal Failure With Renal Transplant

United States
Guangdong Provincial People's Hospital
Novartis

Unknown

Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor

Neuroendocrine Tumors | Carcinoid Tumor

China
Armin Goralczyk

Unknown

Safety Study of Calcineurin-Inhibitor-Free Immunosuppression After Liver Transplantation (CILT)

Liver Transplantation | Chronic Renal Insufficiency

Germany
Novartis Pharmaceuticals

Completed

Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs (COOPERATE-1)

Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System

Germany
Novartis Pharmaceuticals

Completed

Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients

Kidney Transplant

United States, Canada
Leiden University Medical Center

Unknown

Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer

Head and Neck Cancer

Netherlands
ARCAGY/ GINECO GROUP

Completed

Everolimus in Treating Patients With Relapsed or Metastatic Endometrial Cancer (ENDORAD)

Endometrial Cancer

France
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Everolimus in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
Memorial Sloan Kettering Cancer Center
University of Pennsylvania; Dana-Farber Cancer Institute; Novartis Pharmaceuticals

Completed

Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity

Malignant Pleural Mesothelioma

United States
Centre Leon Berard

Suspended

A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas (CHONRAD)

Chondrosarcoma

France
University of Miami
Novartis Pharmaceuticals

Completed

Myfortic vs. Cellcept in Kidney Transplant Recipients

End Stage Renal Disease

United States
Hospital do Rim e Hipertensão

Completed

Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation (SEM)

Kidney Transplant Infection

Brazil
University Hospital, Limoges

Completed

Pharmacokinetics of Immunosuppressive Drugs in Heart Transplant Patients (PIGREC)

Heart Transplant

France
Novartis Pharmaceuticals

Completed

SOCRATES: Steroid or Cyclosporine Removal After Transplantation Using Everolimus

Renal Transplanted Recipients

Australia
Umberto I Hospital, Frosinone Italy

Unknown

Study of ABSORB Stent in Acute Myocardial Infarction (ABSORB-ACS)

Acute Myocardial Infarction | Artery; Deformity, Coronary (Acquired)

Italy
Asan Medical Center

Completed

RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment

Stomach Neoplasm

Korea, Republic of
Samsung Medical Center

Completed

Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors

Solid Tumor

Korea, Republic of
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Terminated

Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas

Sarcoma

United States

3

Subscribe